Amgen (NASDAQ:AMGN) Given New $350.00 Price Target at Cantor Fitzgerald

Amgen (NASDAQ:AMGN) had its target price boosted by investment analysts at Cantor Fitzgerald from $315.00 to $350.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the medical research company’s stock. Cantor Fitzgerald’s price objective points to a potential downside of 3.64% from the company’s current price.

A number of other research firms have also commented on AMGN. Wells Fargo & Company lifted their price target on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. The Goldman Sachs Group boosted their target price on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank Of Canada lifted their price objective on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday. Morgan Stanley increased their target price on Amgen from $304.00 to $309.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $346.35.

Amgen Stock Up 7.3%

Shares of AMGN traded up $24.63 during mid-day trading on Wednesday, hitting $363.22. 1,870,433 shares of the company’s stock were exchanged, compared to its average volume of 2,717,227. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen has a twelve month low of $261.43 and a twelve month high of $360.98. The firm has a fifty day moving average of $332.76 and a two-hundred day moving average of $310.04. The stock has a market cap of $195.59 billion, a price-to-earnings ratio of 28.03, a P/E/G ratio of 3.03 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts forecast that Amgen will post 20.62 earnings per share for the current year.

Insider Transactions at Amgen

In related news, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This trade represents a 14.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This represents a 11.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,908 shares of company stock worth $3,674,966 in the last 90 days. 0.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AMGN. KLCM Advisors Inc. lifted its holdings in Amgen by 15.8% during the fourth quarter. KLCM Advisors Inc. now owns 1,343 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 183 shares in the last quarter. Trek Financial LLC boosted its holdings in Amgen by 6.1% in the 4th quarter. Trek Financial LLC now owns 6,397 shares of the medical research company’s stock worth $2,094,000 after buying an additional 368 shares during the period. Fusion Capital LLC increased its stake in Amgen by 1.5% in the 4th quarter. Fusion Capital LLC now owns 26,062 shares of the medical research company’s stock worth $8,530,000 after buying an additional 380 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs lifted its position in shares of Amgen by 6.2% in the fourth quarter. AG2R LA Mondiale Gestion D Actifs now owns 21,513 shares of the medical research company’s stock valued at $7,041,000 after acquiring an additional 1,264 shares in the last quarter. Finally, Nicholas Company Inc. purchased a new position in shares of Amgen in the fourth quarter valued at about $5,373,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 results beat Street estimates — Amgen reported stronger-than-expected revenue and EPS and issued FY2026 guidance (EPS range 21.60–23.00) that supports a robust outlook, driving positive investor reaction. Amgen quarterly results beat Street estimates
• Positive Sentiment: Goldman Sachs raised its price target to $415 and kept a Buy rating — a high-profile upgrade that signals material upside and likely supported buying. Goldman Sachs adjusts price target on Amgen
• Positive Sentiment: Long-term shareholder returns highlighted — Forbes notes Amgen’s decade-long capital-return program (~$86B), reinforcing appeal to income/total-return investors. Why Amgen Stock Is Paying Off Big For Long-Term Investors
• Positive Sentiment: Company-level execution: double-digit revenue and EPS growth in 2025 and product portfolio/pipeline momentum point to continued growth drivers. Amgen posts double-digit revenue and EPS growth for 2025
• Neutral Sentiment: RBC and Leerink raised price targets (to $360 and $355, respectively) but those targets are near the stock’s current level, implying limited incremental upside. RBC raises price target on Amgen Leerink Partners raises target
• Neutral Sentiment: Reported spikes in short-interest data in feeds appear to be erroneous (zero-share reports); not a material driver based on available data. Article source: internal short-interest entries
• Negative Sentiment: Morgan Stanley’s raise to $309 came with an Equal Weight rating — that target implies downside versus current levels and suggests some investors/analysts remain cautious. Morgan Stanley raises price target on Amgen
• Negative Sentiment: Analysts flag execution and legacy-product erosion risks, and Seeking Alpha highlights emerging regulatory tensions around Tavneos — these are potential downside/catalyst-risk items for the stock. Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
• Negative Sentiment: Some analysts keep Hold ratings (e.g., Citi), reflecting concerns that could limit further rerating despite strong results. Amgen: Solid new-product uptake offset by legacy erosion

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.